MedTrace Logo

Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

NCT01162967 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2013-09-10

No results posted yet for this study

Summary

The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. Exploratory trial of posaconazole antiparasitic activity against Trypanosoma cruzi.

Conditions

  • Chagas Disease

Interventions

DRUG

Benznidazole

Standard dosage

DRUG

Posaconazole

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • Tropical Medicine and International Health Unit Drassanes. Barcelona

    collaborator UNKNOWN

  • International Health Unit Metropolitana Nord. Santa Coloma.

    collaborator UNKNOWN

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Molina Israel, MD · Infectious Disease Department Vall d'Hebron Hospital

  • Pahisssa Albert, MD Ph · Infectious Disease Department Vall d'Hebron Hospital

  • Gomez Jordi, MD · International Health Unit Drassanes

  • Valerio Lluis, MD · International Health Unit Metropolitana Nord

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01162967 on ClinicalTrials.gov